QL1706 plus chemo before surgery for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between ages 18 and 70.
- You have a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma that has not been treated yet.
- Your cancer stage is either IB3, IIA2, or IIICr (a certain spread without involving the lower vagina or certain tissues).
- You have at least one tumor that can be seen on a CT or MRI scan.
- You are in good overall health (able to perform daily activities) and your organs (like heart, kidney, liver, and blood counts) are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
This trial tests whether adding a new immunotherapy drug (QL1706) to chemotherapy before radiation treatment can help patients with advanced cervical cancer that hasn't spread to distant organs. The goal is to improve outcomes and survival.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy for women with advanced or recurrent endometrial cancer that hasn't been treated yet. It may help shrink or control the cancer.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
This trial tests a new drug called QL1706 combined with chemotherapy given before surgery for people with early-stage, high-risk breast cancer that is estrogen receptor positive (ER+) and HER2 negative. The goal is to see if this combination can shrink tumors more effectively before surgery.
Hear when a new Neoadjuvant Treatment for Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.